Conferences - Results from #8120

ASCO GU 2017: Advances in the Understanding and Treatment of Androgen-Receptor-Indifferent Prostate Cancer - Session Highlights February 16, 2017

ASCO GU 2017: Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG S9921) NCT00004124. - Session Highlights February 16, 2017

ASCO GU 2017: The long tail of significantly mutated genes in prostate cancer - Session Highlights February 16, 2017

ASCO GU 2017: Genomic Evolution in Primary and Therapy-Resistant Prostate Cancer - Session Highlights February 16, 2017

ASCO GU 2017: Using Liquid Biopsies to Interrogate Circulating Tumor Clone Dynamics and Prostate - Session Highlights February 16, 2017

ASCO GU 2017: Prostate cancer meta-analysis from more than 145,000 men to identify 65 novel prostate cancer susceptibility loci - Session Highlights February 16, 2017

ASCO GU 2017: Active Surveillance Patient Perspective Question and Answer Panel - Session Highlights February 16, 2017

ASCO GU 2017: Genomic Tests in Active Surveillance and the Role of Hereditary Testing - Session Highlights February 16, 2017

ASCO GU 2017: Imaging To Guide Active Surveillance - Session Highlights February 16, 2017

ASCO GU 2017: What ProtecT Tells Us About Active Surveillance - Session Highlights February 16, 2017

ASCO GU 2017: Canadian Vs. U.S. Guidelines on Active Surveillance - Session Highlights February 16, 2017

ASCO GU 2017: Welcome Address to the Genitourinary Cancer Symposium 2017 - Session Highlights February 16, 2017

ASCO GU 2017: Some Patients Experience Long-Term Tumor Control Even After Stopping Immunotherapy Early February 13, 2017

ASCO GU 2017: Blood Test Uncovers Potential New Treatment Targets in Advanced Prostate Cancer February 13, 2017

ASCO GU 2017: In Advanced Kidney Cancer, Antibiotic Use Lowers Efficacy of Immunotherapy February 13, 2017

Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP) February 7, 2017

Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223. February 7, 2017

Role of FSH in the musculoskeletal side effects associated with androgen deprivation therapy (ADT) for prostate cancer February 7, 2017

2017 Genitourinary Cancers Symposium Press Program to Feature Research Advances in Prostate, Urothelial, Kidney Cancers January 31, 2017

SUO 2016: Immunotherapy for Prostate Cancer: What is the Way Forward? - Session Highlights December 2, 2016

Page 407 of 507